Subsequent Events (Additional Information (Details) - USD ($)								3 Months Ended	9 Months Ended
	Oct. 08, 2026	Jan. 02, 2025	Dec. 11, 2024	Oct. 28, 2024	Oct. 27, 2024	Oct. 08, 2024	Oct. 07, 2024	Sep. 30, 2024	Sep. 30, 2024	Aug. 09, 2024	Jun. 18, 2024	Jun. 11, 2024	Dec. 31, 2023	Oct. 11, 2023	Mar. 21, 2023
Subsequent Event [Line Items]
Warrants outstanding								5,467,692	5,467,692				6,854,309
Proceeds from warrant exercises								$ 400,000	$ 500,000
Common stock, shares issued								191,790,520	191,790,520		3,250,000	3,250,000	160,084,250
Preferred stock, par value								$ 0.0001	$ 0.0001				$ 0.0001
Aggregate shares issued, common stock									250,000
Maximum [Member]
Subsequent Event [Line Items]
Common stock at a conversion price														$ 2
Convertible Promissory Note [Member]
Subsequent Event [Line Items]
Common stock at a conversion price										$ 10
Convertible Promissory Note [Member] | Principal Balance [Member]
Subsequent Event [Line Items]
Debt principal amount										$ 15,063.74
Convertible Promissory Note [Member] | Remaining Drawable Balance [Member]
Subsequent Event [Line Items]
Debt principal amount										164,936.26
Convertible Promissory Note [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt principal amount										$ 180,000
Registered Direct Offering [Member]
Subsequent Event [Line Items]
Warrants outstanding								15,000,000	15,000,000
Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Redemption price percentage									10.00%
Common stock at a conversion price															$ 8
Forecast [Member]
Subsequent Event [Line Items]
Amortization payment	$ 1,110,000
Royalty rate percentage		4.00%
Royalty agreement description		The Term Sheet provides that the Company and the Tranche B Noteholders would enter into an agreement pursuant to which the Tranche B Noteholders shall collectively receive a 10 year, assignable, freely transferable, 4% royalty (the “Royalty”)
Forecast [Member] | Deferral and Consent under Tranche B Senior Secured Convertible Note
Subsequent Event [Line Items]
Debt principal amount		$ 6,250,000
Redemption price percentage		100.00%
Forecast [Member] | Oramed
Subsequent Event [Line Items]
Total number of shares granted		2,500,000
Forecast [Member] | Scilex Pharmaceuticals
Subsequent Event [Line Items]
Total number of shares granted		5,000,000
Forecast [Member] | BPY Limited
Subsequent Event [Line Items]
Total number of shares granted		720,000
Forecast [Member] | Nomis Bay Ltd
Subsequent Event [Line Items]
Total number of shares granted		1,280,000
Forecast [Member] | 3i, LP
Subsequent Event [Line Items]
Total number of shares granted		500,000
Subsequent Event [Member] | Declaration of Preferred Stock Dividend [Member]
Subsequent Event [Line Items]
Preferred stock dividend shares					5,000,000
Preferred stock, par value				$ 0.0001	$ 0.0001
Common stock shares exercise price					$ 11.5
Unissued preferred stock				5,000,000
Conversion of common stock				$ 200,000,000
Preferred stock number of shares rate to pro rata portion				10.00%
Subsequent Event [Member] | December RDO
Subsequent Event [Line Items]
Proceeds from issuance of warrants			$ 17,000,000
Subsequent Event [Member] | Amendment to Common Stock Purchase Warrant
Subsequent Event [Line Items]
Warrants exercised price			$ 0.59
Proceeds from warrant exercises			$ 1,041,000.000
Subsequent Event [Member] | Common Stock [Member] | December RDO
Subsequent Event [Line Items]
Aggregate shares issued, common stock			26,355,347
Subsequent Event [Member] | Common Stock [Member] | Amendment to Common Stock Purchase Warrant
Subsequent Event [Line Items]
Warrants outstanding			1,764,706
Subsequent Event [Member] | Common Warrants | Common Stock [Member] | December RDO
Subsequent Event [Line Items]
Offering price per share			$ 0.59
Subsequent Event [Member] | October Common Warrants | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Warrants exercised price							$ 1.09
Warrant, exercise price, decrease							$ 1.04
Subsequent Event [Member] | Pre-Funded Warrants | Common Stock [Member] | December RDO
Subsequent Event [Line Items]
Warrants execiseable			2,401,132
Offering price per share			$ 0.5899
Subsequent Event [Member] | December Common Warrants | Common Stock [Member] | December RDO
Subsequent Event [Line Items]
Warrants execiseable			57,512,958
Subsequent Event [Member] | Investor Agreement [Member] | Common Stock [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Amount received in exchange for issuance of the New Notes							$ 22,500,000
Subsequent Event [Member] | Investor Agreement [Member] | October Common Warrants | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Common stock, shares issued							3,750,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Decrease in common stock at a conversion price							$ 1.04
Non accountable legal fees							$ 950,000
purchase price at the closing of the transaction							20,000
Placement agent's fees							2,000,000
Debt principal amount							$ 50,000,000
Common stock at a conversion price							$ 1.09
Subsequent Event [Member] | Securities Purchase Agreement [Member] | October Common Warrants | Common Stock [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Warrants execiseable							7,500,000
Subsequent Event [Member] | Securities Purchase Agreement and Royalty Purchase Agreement [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Proceeds from debt, net of issuance costs						$ 20,800,000
Subsequent Event [Member] | Oramed | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Net proceeds for repayment						12,500,000
Subsequent Event [Member] | Oramed | Investor Agreement [Member] | October Common Warrants | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Common stock, shares issued							3,750,000
Subsequent Event [Member] | Oramed | Securities Purchase Agreement [Member] | New Tranche B Notes [Member] | Principal Balance [Member]
Subsequent Event [Line Items]
Reduction of the principal balance							$ 22,500,000
Subsequent Event [Member] | Oramed | Royalty Purchase Agreement [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Amount paid for purchased receivables						2,500,000
Amount extinguished and reduced						$ 2,500,000
Subsequent Event [Member] | Rodman & Renshaw LLC | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Common stock, shares issued							2,197,802
Trading volume of common stock							8.00%
Common stock trading price per share rates							10.00%
Common stock at a conversion price							$ 1.09
Subsequent Event [Member] | Rodman & Renshaw LLC | October Common Warrants | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Common stock, shares issued							3,669,724
Subsequent Event [Member] | Scilex Pharmaceuticals | Royalty Purchase Agreement [Member]
Subsequent Event [Line Items]
Federal funds purchased, average rate paid						8.00%
Subsequent Event [Member] | Scilex Pharmaceuticals | Royalty Purchase Agreement [Member] | New Tranche B Notes [Member]
Subsequent Event [Line Items]
Purchase price for the purchased receivables						$ 5,000,000
Paid to royalty investors						$ 2,500,000